Spanish Government Moves to Ban Pseudo-therapies
According to a survey carried out by the Spanish Foundation for Science and Technology (FECYT) over half of the Spanish population believe Pseudo-therapies to be of real value. “Public…
The Indukern Group is a group of Spanish multinational companies founded in 1952 based in Madrid. Its main activities are focused on the pharmaceutical, chemical, food and veterinary industries, among others through its three business areas; Indukern, Calier, and Kern Pharma.
With five business divisions, Indukern is a leading specialist firm in chemicals distribution and value-added activities of formulation, production, and technical advice for various industry sectors.
Calier is a research, development and marketing company of pharmacological and biological products for livestock and pets.
Kern Pharma works in the development, manufacture and marketing of pharmaceutical products, with emphasis on generics and ethicals. It also markets products for the OTC market, biosimilars, women’s health, health and sports nutrition, and production for other companies.
According to a survey carried out by the Spanish Foundation for Science and Technology (FECYT) over half of the Spanish population believe Pseudo-therapies to be of real value. “Public…
Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he…
Xavier Carbonell, CEO of Palex Group, a leading Spanish medical device player, discusses how the company’s growth has been triggered by acquisitions to grow their portfolio and distribution arm, as…
After a recent course of political shifts, Spain now finds itself with a new minister of health; the third since this past June. Maria Luisa Carcedo, who was named as…
Carlos Espina, managing director of COMSA Cleanroom Technology, a leading Spanish engineering firm, highlights the company’s great successes over the last few years, their international reach, and their strategy to…
Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches…
Although death rates due to cardiovascular diseases in Spain are among the lowest in the EU, they represent the main cause of death in Spain, accounting for 30% of all…
Kerman Elordi, managing director of Nekicesa, describes the key trends impacting the pharmaceutical and packaging industries, how the company leverages innovation to meet market needs a first mover in technology,…
Fernando Prados Roa, deputy minister of health for Madrid, discusses the health paradigm of the community and elaborates on the role of SERMAS in managing and coordinating the city’s public…
Baltasar Lobato, managing partner of health and life sciences at EY Spain, highlights the major market trends affecting the public and private healthcare sector as well as the pharmaceutical market.…
The global rich list is splattered with household names who have built their reputation not only through business acumen but through eye-catching purchases such as Steve Balmer’s record buyout of…
LEO Pharma’s Paolo Cionini discusses recent structural changes in the dermatology specialist’s Europe South operations, the importance of Spain to the regional group, and the nation’s digital capabilities. The…
See our Cookie Privacy Policy Here
